Your browser doesn't support javascript.
loading
Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma.
Decraene, B; Vanmechelen, M; Clement, P; Daisne, J F; Vanden Bempt, I; Sciot, R; Garg, A D; Agostinis, P; De Smet, F; De Vleeschouwer, S.
Afiliação
  • Decraene B; KU Leuven, Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Leuven, Belgium.
  • Vanmechelen M; KU Leuven Department of Neurosciences, Experimental Neurosurgery and Neuroanatomy Research Group, Leuven, Belgium.
  • Clement P; Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.
  • Daisne JF; KU Leuven, Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Leuven, Belgium.
  • Vanden Bempt I; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Sciot R; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Garg AD; Radiation Oncology Department, University Hospitals Leuven, Leuven, Belgium.
  • Agostinis P; Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium.
  • De Smet F; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  • De Vleeschouwer S; KU Leuven, Laboratory of Cell Stress & Immunity (CSI), Department of Cellular & Molecular Medicine, Leuven, Belgium.
Cancer Med ; 12(10): 11107-11126, 2023 05.
Article em En | MEDLINE | ID: mdl-36776000
Glioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite extensive therapy, which consists of maximal safe surgical resection, radiotherapy, and/or chemotherapy. Recently, it has become clear that GBM is not one homogeneous entity and that both intra-and intertumoral heterogeneity contributes significantly to differences in tumoral behavior which may consequently be responsible for differences in survival. Strikingly and in spite of its dismal prognosis, small fractions of GBM patients seem to display extremely long survival, defined as surviving over 10 years after diagnosis, compared to the large majority of patients. Although the underlying mechanisms for this peculiarity remain largely unknown, emerging data suggest that still poorly characterized both cellular and molecular factors of the tumor microenvironment and their interplay probably play an important role. We hereby give an extensive overview of what is yet known about these cellular and molecular features shaping extreme long survival in GBM.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica